Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $25.50.
KURA has been the topic of a number of research reports. UBS Group decreased their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st.
Read Our Latest Stock Report on Kura Oncology
Insider Activity at Kura Oncology
Hedge Funds Weigh In On Kura Oncology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. Virtus ETF Advisers LLC boosted its position in Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new position in Kura Oncology in the 4th quarter valued at approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 4th quarter valued at approximately $90,000. Corton Capital Inc. purchased a new position in Kura Oncology in the 4th quarter valued at approximately $99,000. Finally, Optimize Financial Inc purchased a new position in Kura Oncology in the 4th quarter valued at approximately $100,000.
Kura Oncology Trading Up 2.1 %
Shares of Kura Oncology stock opened at $7.29 on Friday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $7.84 and its 200 day moving average price is $12.75. Kura Oncology has a twelve month low of $6.79 and a twelve month high of $23.48. The firm has a market capitalization of $588.70 million, a PE ratio of -3.09 and a beta of 0.85.
Kura Oncology (NASDAQ:KURA – Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, sell-side analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
See Also
- Five stocks we like better than Kura Oncology
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Can TikTok Stock Picks Really Make You Rich?
- What is the Shanghai Stock Exchange Composite Index?
- The “Quality” Rotation: Back to Basics Investing
- What Investors Need to Know to Beat the Market
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.